Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Trial of Sleeping Beauty-Modified Third-Generation Anti-CD19 CAR T-Cell Therapy (TCRs) to Treat Solid Tumors

Next Previous
Trial Profile

A Phase 1 Trial of Sleeping Beauty-Modified Third-Generation Anti-CD19 CAR T-Cell Therapy (TCRs) to Treat Solid Tumors

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti CD19 chimeric antigen receptor T cell therapy Alaunos Therapeutics (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 08 Aug 2019 According to a ZIOPHARM Oncology media release, this trial is expected to begin in late 2019.
    • 05 Mar 2019 According to a ZIOPHARM Oncology media release, The Company affirms guidance on beginning this trial and treating patients at MD Anderson Cancer Center in the second half of this year.
    • 09 Oct 2018 According to a ZIOPHARM Oncology media release, the company have affirmed its guidance on this planned phase I study.The IND application for this phase 1 trial remains on track to be submitted in the fourth quarter of 2018 followed by enrollment of patients beginning in 2019, pending regulatory clearance.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top